Efficacy and safety of glucagon-like peptide-1 receptor agonists in Parkinson’s disease: a systematic review and meta-analysis of randomized placebo-controlled clinical trials

Maria-Ioanna Stefanou, Evangelos Panagiotopoulos, Anastasios Tentolouris, Aikaterini Theodorou, Georgia Papagiannopoulou, Athanasia Athanasaki, Panagiota-Eleni Tsalouchidou, Melpomeni Peppa, Vaia Lambadiari, Spiridon Konitsiotis, Annerose Mengel, Georgios P. Paraskevas, Nikolaos Tentolouris, Georgios Tsivgoulis

Therapeutic Advances in Neurological Disorders

Published online on January 31, 2026

Abstract

Therapeutic Advances in Neurological Disorders, Volume 19, January-December 2026.
Background:Converging lines of preclinical evidence support the neuroprotective properties of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Parkinson’s disease (PD). Nevertheless, results from randomized-controlled clinical trials (RCTs) remain ...